South Korea's semiconductor exports from Nov. 1-10 rose 331.2% year-on-year.

Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed first‑participant dosing in an Australia Phase I/II study today. Preclinical data show strong inhibition in tumor cells and xenograft models with diverse RAS mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic, non‑small‑cell lung and colorectal cancers, and report favorable pharmacokinetics and safety.

美国国务卿鲁比奥：乌克兰谈判应有欧洲参与。